Novotech appoints DatelineMedia (USA) as Communications

Dec 7, 2004 – San Francisco, CA – Novotech, Australia’s leading clinical research organization (CRO), has appointed DatelineMedia Communications (USA) as its agency of record for PR and media strategy in the U.S. Alek Safarian, Novotech CEO, said editorial media coverage played a significant role in the company’s business development program in the U.S. and [...]

U.S. Biotech and Pharma Industry leaders gather

Oct 14, 2004 – Washington DC — Novotech, Australia’s leading contract research organization (CRO), and the Australian Embassy are hosting a clinical trials and biopartnering networking event next week to showcase the considerable business opportunities for U.S. biotech and pharma in Australia. Date: October 25, 2004 Time: 6.30pm – 8.30pm (Australian food and wine to [...]

Australian-based CRO Novotech unveils plans to open in the U.S

June 6, 2004 – San Francisco, CA — Riding on a wave of successful bids for U.S clinical trials contracts, Novotech CEO Alek Safarian will outline plans to open operations in the U.S. at this week’s BIO 2004, San Francisco (www.bio.org ). During the conference Safarian will host functions with biotech executives and VCs to [...]

Novotech eases drug development bottleneck

April 26, 2004 – Orlando, Florida — Clinical research trials in Australia can begin in as little as 2-3 months from the initiation of the approval process and cost up to 30% less than comparable Western countries such as the US and Europe. Alek Safarian, CEO of Australia’s largest CRO Novotech said Australian regulatory procedures [...]

FDA approves Tarceva for patients with advanced…

March 31, 2004 – Sydney, Australia — Novotech, Australia’s leading contract research organization (CRO), today announced that it was involved in the highly successful trial for Tarceva ™ (erlotinib) which was recently approved by the U.S. Food and Drug Administration (FDA), after priority review. Tarceva ™, produced by OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Genentech, [...]